Registered title, quoted from ClinicalTrials.gov
Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
An open trial on multiple myeloma, registered on ClinicalTrials.gov. Led by Chinese PLA General Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07489534, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
14 years to Not stated; sex: all
Registered eligibility fields
Diagnosed with multiple myeloma accompanied by renal dysfunction, received ≥ 2 courses of clinical first-line treatment, evaluated efficacy above PR, and predicted survival of more than three months.
Inclusion criterion 2
ECOG physical status score 0-2 or KPS score>80 points
Inclusion criterion 4
WBC≥1×109/L,LY≥0.3×109/L,
Inclusion criterion 6
ALT and AST ≤ 2.5 ULN
Inclusion criterion 7
Serum total bilirubin ≤ 2.0mg/dL (34.2 μmol/L)
Inclusion criterion 8
HIV/AIDS infection;
Exclusion criterion 4
Pregnant or lactating women (the safety of this treatment for unborn babies is unknown, and the assessment of pregnancy status for female participants is negative in serum or urine pregnancy tests within 48 hours prior to infusion);
Exclusion criterion 1
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07489534, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age: Over 14 years old
- Diagnosed with multiple myeloma accompanied by renal dysfunction, received ≥ 2 courses of clinical first-line treatment, evaluated efficacy above PR, and predicted survival of more than three months.
- The hospital examination meets the following indicators:
- ECOG physical status score 0-2 or KPS score>80 points
- Having sufficient venous access for single or intravenous blood collection, and no other blood cells Separation contraindications
- WBC≥1×109/L,LY≥0.3×109/L,
- ALT and AST ≤ 2.5 ULN
- Serum total bilirubin ≤ 2.0mg/dL (34.2 μmol/L)
- PT:INR<1.7 or PT prolonged by<4s compared to normal value
Exclusion Criteria:
- Pregnant or lactating women (the safety of this treatment for unborn babies is unknown, and the assessment of pregnancy status for female participants is negative in serum or urine pregnancy tests within 48 hours prior to infusion);
- Any uncontrollable active infection;
- Presence of active hepatitis B or C virus infection;
- HIV/AIDS infection;
- Has neurological disorders;
- Within 2 weeks prior to signing the informed consent form, systemic use of steroid drugs (inhalable steroids may be used);
- Allergies to immunotherapy and related drugs;
- Currently, there are patients with heart disease or poorly controlled hypertension who require treatment;
- Currently, patients with unstable or active ulcers or gastrointestinal bleeding;
- Patients with a history of organ transplantation or waiting for organ transplantation;
- Hyponatremia, blood sodium<125mmol/L;
- Baseline blood potassium<3.5mmol/L (potassium can be supplemented before participating in the study to restore blood potassium levels above this level);
- The patient needs anticoagulant therapy (such as warfarin or heparin);
- The patient requires long-term antiplatelet therapy (aspirin, dose>300mg/d); Clopidogrel, dose>75mg/d).
Additionally,
- Patients currently participating in other clinical trials;
- Researchers believe that other reasons are not suitable for clinical trial participants.
Quoted from ClinicalTrials.gov, NCT07489534, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07489534, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.